





VAccine monitoring Collaboration for Europe

Timely real world evidence to monitor COVID-19 vaccine Academic/investigator EU perspective

Prof. dr. Miriam Sturkenboom

Head of department Datascience & Biostatistics, UMC Utrecht VAC4EU president Partner in EU PE&PV network led by University Utrecht







VAccine monitoring Collaboration for Europe

Readiness & collaboration is key to generation of timely and robust RWE for benefit risk monitoring of COVID-19 vaccines



EUROPE: READY DUE TO LESSONS LEARNED IN H1N1 PANDEMIC AND THE IMI FUNDED ADVANCE PROJECT FROM 2013-2019



Vaccine Volume 38, Supplement 2, 22 December 2020, Pages B1-B7



Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines

Miriam Sturkenboom ^{a, b, c} A , Priya Bahri ^d , Antonella Chiucchiuini ^e , Tyra Grove Krause ^f , Susan Hahné ^g , Alena Khromava ^h , Maarit Kokki ⁱ , Piotr Kramarz ⁱ , Xavier Kurz ^d , Heidi J. Larson ^j , Simon de Lusignan ^{k, I} , Patrick Mahy ^m , Laurence Torcel-Pagnon ⁿ , Lina Titievsky ^o , Vincent Bauchau ^p , on behalf of the ADVANCE consortium ¹ IMI-ADVANCE (Accelerated Development of VAccine beNefit-risk Collaboration in Europe)

- **Governance readiness**: code of conduct and governance for collaborative vaccine studies.
- Methods readiness
- Data source readiness
- Study readiness





ADVANCE 2019: TESTED SYSTEM & GOVERNANCE PLUS ORGANIZATION



After five years the ADVANCE project has managed to deliver a Blueprint document based on the project outputs, summarising methods, infrastructure, scenarios and sustainability for conducting different types of studies related to post-marketing vaccine coverage, benefit and risk monitoring.



Review

Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe

Laurence Torcel-Pagnon^{a,*}, Vincent Bauchau^b, Patrick Mahy^c, Myint Tin Tin Htar^d, Marianne van der Sande^{e,f,g}, Cédric Mahé^a, Tyra Grove Krause^h, Anne Charrat^a, François Simondon^{i,j}, Xavier Kurz^k, on behalf of the ADVANCE Consortium^{*}



VAccine monitoring Collaboration for Europe


- Non-for profit International association established January 2020
- Member based organization, set up by membership fees
- Shared tools, infrastructures & processes
- Access to data across multiple organizations
- Rotation of roles/responsibilities





READINESS: Expertise & Data access in EU

VAccine monitoring Collaboration for Europe



- 24 members (expertise and/or data access)
- Access to large national/regional health data from different provenance (Registries/medical record/hospitalizations/insurance) >130 M

Country	Type of health data sources	# persons
NL	Record linkage	6 Million
NO	Record linkage	5 million
DK	Record linkage	5.5 million
IT (4)	Medical records (GP/FP Regional record linkage	12 million
ES (4)	Record linkage & medical records	30 million
UK	Medical records & HES	16 million
DE	Insurance	16 million
FR	SNDS (Claims)	60 million


Classified as internal/staff & contractors by the European measures agency



READINESS:

Generic distributed analytics pipeline


Individual level original data stay local, unless consented



Utilizing the generic RWD-RWE pipeline developed in the last 10 years across EU-ADR, IMI-ADVANCE and IMI-ConcePTION projects

CDM description: https://www.imi-conception.eu/wp-content/uploads/2020/10/ConcePTION-D7.5-Report-on-existing-common-data-models-and-proposals-for-ConcePTION.pdf

EMA tendered independent research to prepare for COVID-19 vaccine monitoring through Framework program (EU PE&PV network and VAC4EU)



List of AESI


Background rates of AESI

Template protocols

May 2020


January 2021

Classified as internal/staff & contractors by the European Medicines Agency



Public template protocols for different types of data collection (Delivered December 2020)

- Signal detection based on cohort event monitoring (EUPAS 38915)
- Three types of safety protocols for assessment of safety (EUPAS39361)
 - Rapid assessment of safety signals
 - Safety evaluation of COVID-19 vaccines through electronic health records
 - Safety Protocol for Hospital Case–Based Monitoring
- Effectiveness studies (EUPAS39289)
- Coverage study (EHR/registry based) (EUPAS39361)



Background rates of AESI


- List of 41 AESI based on SPEAC (August 2020)
- Definition and code lists publicly available (Sept 2020) (see zenodo)
- Protocol registered in EUPAS and publicly available (September 2020)
 - Using common data model and analytics
 - 10 data sources, 7 countries
- Age, gender and time specific background rates generated and publicly available February, April and June
 - Zenodo: https://doi.org/10.5281/zenodo.5255870
- Data used for O/E analyses by EMA and manufacturers
- Ability to rapidly provide data on new events (e.g. TTS)
- Focus on type of outcome data (primary care/hospital)

https://vac4eu.org/covid-19-tool/

Report, definitions and data all available

Ē	=	🗎 zenodo.org	Ċ	1
Mail - M.C.J.Sturkenboom@um	cutrecht.nl	ConcePTION_CDM tables v2.2.xlsx - Google Sheets	Background rates of Advers	e Events of Special Interest for monitoring COVID-19
zenod	Search	Q Upload Communities		€ Sign up
<u> </u>		Report Open Access	1,702 ® views	737 ± downloads
Willame, C; Dodd, C; Gini, Moore, N; Haug, U; Schin Aragón, M; Perez-Guttha	R; Durán, CE; Thomsen, RM; Wang, L <, T; Diez-Domingo, J; Mira-Iglesias, A 1n ,S; Arana, A; Giaquinto, C; Barbieri,	COVID-19 vaccines L; Gedebjerg, A; Kahlert, J; Ehrenstein, V; Bartolini, C; Droz, C; A; Vergara-Hernández, C; Carreras, JJ; Villalobos, F; Pallejà, M; E; Stona, L; Huerta, C; Pallejà, M; Aragón, M; García Poza, P; de H; Siiskonen, SJ; Weibel, D; Mahy, P; Klungel, O; (0)	See more de	stails
Sturkenboom, MCJM Rationale and backgrou The global rapid spread of	nd: of COVID-19 caused by the SARS-Co	Y-2 triggered the need for developing vaccines to control for idence rates of adverse events of special interest (AESI) that		AIRE
	penefit-risk profile of COVID-19 vacci			
United Kingdom). Data s (PHARMO, Danish registr	ources contain health insurance data	ies (Denmark, Germany, France, Italy, Netherlands, Spain, a (GePaRD, SNDS), hospitalisation record linkage data rom general practitioners (CPRD, PEDIANET, BIFAP, FISABIO).	Publication date: August 25, 2021 DOI: DOI 10.5281/zenodo.52558	70
number of 45 million ind		ately 141.6 million individuals. In this final report, a total cluding French data is expected later this year	Keyword(s): background rates, AESI, Covid-19 Communities: Vaccine Monitoring Collabo	
Pedianet (children only), not be generated in a tim	CPRD, ARS, Danish registries, FISABI ely manner due to administrative co	countries (UK, ES, IT, DK, NL, DE) and 9 data sources(BIFAP, IO, SIDIAP, PHARMO, GeParD). Data from France (SNDS) could nstraints in data release. Data sources included different f the observed persontime (Hosp= hospital based, PC=	License (for files):	
	overlap between hospitalization and he results in excel format and also th	l primary care). he links to the codes and event definitions	Versions	
This protocol has been	accepted by EMA as a deliverable o	of the framework contract No EMA/2018/28/PE. The	Version 2.0	Aug 25, 2021

Example VTE or Arterial thrombosis with thrombocytopenia by age



Incidence rate (+ 95% CI)

x-axis is generated automatically


Section monitoring readinESS

ACCESS

vACCine covid-19

Willame et alsahttps://doirorg/10.5281/zenodo.5255870

EMA funded research to monitor COVID-19 vaccines



Classified as internal/staff & contractors by the European Medicines Agency

EMA funded independent research to monitor COVID-19 vaccines

1. Monitoring event rates post-vaccination Cohort event monitoring: EUPAS42504, EUPAS39798 Cohort study using EHR data sources: EUPAS40404 & EUPAS40414


2. Testing signals

Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care data sources (EUPAS42467) Covid-19 Vaccine Monitor-EHR

From: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/monitoring-covid-19-mediciness@ied as internal/staff & contractors by the European Medicines Agency

Cohort event monitoring-1 ending Nov. 2021 Early Covid-19 Vaccine Monitor: general population






- Inclusion of patients within 2 days after vaccination, follow for 6 months
- Solicited reactogenicity events and serious unsolicited events by vaccine
- Reported monthly to the EMA on interactive dashboard
- Countries: Netherlands, Germany, Belgium, Croatia, Italy, France

Cohort event monitoring-1: ending Nov 2021 Early Covid-19 Vaccine Monitor total of 117,707 patients included

Vaccine brand	Dose 1 (Number of participants, %)	Dose 2 (Number of participants)
AstraZeneca	89356 (75,9%)	55550
BioNtech/Pfizer	14603 (12,4%)	11671
Janssen	2490 (2,1%)	0
Moderna	11258 (9,6%)	8080
Total	117707 (100%)	75301

Coordinated by LAREB Center, the Netherlands (A. Kant, M. Raethke)

Using the Lareb Intensive Monitoring app Displayed on interactive Dashboard for EMA




Any Adverse Reaction within each Age Category (dose 1)

Secretariat@vac4eu.org Classified as internal/staff & contractors by the European Medicines Agency

Cohort event monitoring -2 Covid-19 Vaccine Monitor- Sept 2021-2023





Countries:


• Romenia, Slovakia, Ireland, Switzerland, Spain, France, UK, Italy, Portugal, Netherlands, Belgium

Booster of first vaccination (general population or sub populations) Specific sub populations targeted

- Pregnant women
- Immunocompromised persons
- Former COVID-19
- History of allergies
- Children

Coordinated by University Verona (G. Trifiro) Data collection through UMCU Research online

Cohort event monitoring: Workflow for reported ADRs



From Raethke et al. July Report ECVM)

Classified as internal/staff & contractors by the European Medicines Agency


EMA funded independent research to monitor COVID-19 vaccines

1. Monitoring event rates post-vaccination Cohort event monitoring: EUPAS42504, EUPAS39798 Cohort studies using EHR datasources EUPAS40404 & EUPAS40414

2. Testing signals

Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care data sources (EUPAS42467) Covid-19 Vaccine Monitor-EHR

EHR cohort monitoring of AESI after vaccines EUPAS40404



Non-vaccinated month

Month of vaccination, persontime dose 1 or dose 2 counts from day of vaccination Vaccination date dose 2 T=0 dose 2

Vaccination date dose 1 T=0 dose1

Data sources selected on short lag times:

- BIFAP-ES: 15 million
- Tuscany- IT: 4.5 million
- PHARMO-NL: 3 million
- CPRD-UK: 18 million

Using ConcePTION CDM and pipeline



Status:

- Rates periodically updated and submitted to EMA in past year
- Interactive Dashboard with detailed data available to PRAC April, July, October
- November 2021 final report

Dose		ARS,	Italy	BIFAP,	Spain	PHAR	MO, NL	CPRE), UK	Total
AstraZeneca dose 1		332872	17.6%	537122	13.4%	68655	8.2%	3671672	66.8%	4,610,321
AstraZeneca dose 2		187052	56.2%	397186	73.9%	28779	41.9%	1172745	31.9%	1,785,762
Other vaccine dose 2		7150	2.1%	7298	1.4%			3113	0.1%	
Amongst persons with AstraZeneca dose 2	Min	20		14		70		14		
	P25	84		71		76		70		
distance	P50	84		82		77		77		
	P75	84		84		84		78		
	Max	126		193		155		127		
Janssen dose 1	N	58513	3.1%	201543	5%	22455	2.7%			282,511
Janssen dose 2	N	0	0%	0	0%	0	0%			0
Other vaccine dose 2	N	0	0%	63	0%	15	0.1%			
Moderna dose 1	Ν	184013	9.7%	447401	11.2%	67689	8.1%	27023	0.5%	726,126
Moderna dose 2	N	100673	54.7%	363226	81.2%	25638	37.9%	<5	0%	489,537
Other vaccine dose 2	N	125	0.1%	590	0.1%			9	0%	
Amongst persons with	Min	16		14		21		28		
Moderna dose 2 distance	P25	28		28		35		28		
	P50	28		28		35		28		
	P75	28		28		35		44		
	Max	124		224		160		91		
Pfizer dose 1	Ν	1320326	69.6%	2808700	70.3%	568119	67.6%	1801355	32.8%	6,498,500
Pfizer dose 2	N	653580	49.5%	2372395	84.5%	232351	40.9%	1332285	74%	4,590,611
Other vaccine dose 2	Ν	138	0%	1179	0%			6226	0.3%	
Amongst persons with	Min	14		14		21		14		
Pfizer dose 2 distance	P25	21		21		35		70		
	P50	21		21		35		76		
	P75	21		21		36		78		
	Max	174		244		169		147		

EMA funded independent research to monitor COVID-19 vaccines

1. Monitoring event rates post-vaccination

Cohort event monitoring: EUPAS42504, EUPAS39798 Cohort studies using EHR datasources: EUPAS40404 & EUPAS40414

2. Testing signals

Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care data sources (EUPAS42467) Covid-19 Vaccine Monitor-EHR

Readiness to rapidly quantify signals



Preparedness

- Extract, transform load relevant data into ConcePTION Common Data Model
- Run quality checks & background rates (vaccination data, AESI identification)
- Protocols approved: cohort & SCRI

Data sources:

- Italy (3): Tuscany region, Lazio Region, Caserta
- Spain (3): BIFAP, SIDIAP, FISABIO
- NL (1): PHARMO
- UK (1): CPRD
- No (1): Norwegian registers

Two signal verification requests: MIS and Myocarditis



- Cohort analysis for rates pre and post vaccination
- SCCS for Myocarditis & pericarditis

Status

- Both requests generated information for EMA within one month
- MIS: signal closed by PRAC (very few cases)
- Myocarditis: excess rates in younger persons with mRNA platform vaccines
 - To be discussed in upcoming PRAC

Acute macular neuropathy Thromboembolic events Capillary leak syndrome Anaphylaxis, capillary Erythema multiforme ADEM, Capillary leak syndr. Glomerulonephritis ЧТ leak syndrome Thrombosis & ∞ ∞ Myocarditis pericarditis, encephalitis anaphylaxis Myocarditis pericarditis anaphylaxis Myocarditis pericarditis Death GBS GBS ПР ЦТР MIS AstraZeneca Moderna vaccine Janssen vaccine vaccine vaccine Pfizer Dec 2020 Jan. 2021 Feb. 2021 March 2021 April 2021 May 2021 June 2021 July 2021 Aug. 2021 Sept. 2021 Oct. 2021

Serious new events discussed in PRAC for COVID-19 vaccines

Conclusion

- The ACCESS/SPEAC AESI list has been well predictive for serious issues that occurred
- Incidence rates on 41 events were available for O/E analyses through ACCESS from 9 data sources in Europe, including TTS, GBS, myocarditis
- The ECVM study provided
 - incidence rates of all AESI post vaccination from EHR data (n=12,117,458 vaccinated)
 - Sollicited and non-sollicited ADR rates from 117,707 vaccinated persons who were consented and responded in cohort event monitoring
- The CVM study is focusing on
 - Cohort event monitoring of booster doses and special populations in 10 countries
 - Signal testing capacity in 10 data sources in Europe
- There is an infrastructure and readiness of people, data and tools to address heterogeneity in Europe and leverage the vast amount of expertise and data in ENCePP centers through the EU PE &PV network and VAC4EU





Thanks to all the incredible contributors of all centers in EU PE/PV and VAC4EU

University Medical Center Utrecht, Utrecht, The Netherlands (UMCU), Universiteit Utrecht (UU), Utrecht, Aarhus University, RIVM, Lazio region, Pedianet, Agenzia Regionale di Sanita' Toscana (ARS), LAREB, RTI Health Solutions (RTI-HS), Spain & US, PHARMO Institute, University of Verona, Paul Ehrlich Institut (PEI), Bereich Pharmacovigilanz, Université de Bordeaux, Bordeaux PharmacoEpi (BPE), France, University of Oslo (UiO), Norway, Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Luxembourg Institute of Health (LIH), Spanish Agency on Medicines and Medical Devices (AEMPS) -BIFAP database, London School of Hygiene and Tropical Medicine (LSHTM), Team-it Research SL (TEAMIT), University of Bern, Switzerland, Drug Safety Research Unit (DSRU), UK, CLPP Vaccines Network, Portugal, SLOVACRIN Pavol Jozef Šafárik University in Košice, Faculty of Medicine, Slovakia , Masaryk University, Faculty of Medicine, Brno, Czech Republic

> Keep updated about results <u>https://vac4eu.org/</u> https://zenodo.org/communities/vac4eu/